‘Groundbreaking’ COVID-19 antiviral treatments could be offered to vulnerable patients this winter
The UK Government has announced deals to secure two new antivirals, molnupiravir and PF-07321332/ritonavir, for the treatment of COVID-19, both of which could be rolled out this winter.
The deals, made by the Antivirals Taskforce, are a significant step in its ambition to secure at least two new effective treatments by the end of the year for those who have either tested positive for COVID-19 or have been exposed to someone with the virus.
The antivirals, if approved by the Medicines and Healthcare products Regulatory Agency, will be available to thousands of NHS patients who are most at risk from the virus. The treatments are expected to prevent COVID-19 from spreading and speed up recovery time.
The Government and the NHS are working on plans for deployment of the antivirals, including delivering a national study, which will allow medical experts to gather further data on the potential benefits the treatments bring to vaccinated patients.
Eddie Gray, Chair of the Antivirals Taskforce, said: ‘This is a very important development in our mission to find antivirals for those exposed to COVID-19, supporting the renowned vaccination programme and the NHS over the coming months.
‘Should they be approved by the medicines regulator, we could see these treatments rolled out to patients this winter, providing them with vital protection.’
Lead image: Grispb/sotck.adobe.com
Image 1: Grispb/sotck.adobe.com